Considering the multisymptomatological nature of AD, an alternative strategy to the use of combinations of drugs is the design of novel multitarget ligands that simultaneously enhance cholinergic and serotonergic tone by inhibiting AChE and blocking the serotonin transporter, respectively [20]. The gene discussed is ACHE; the disease is Alzheimer disease.